Daily Brief Health Care: Aier Eye Hospital Group, Agilent Technologies, Pfizer Inc and more

In today’s briefing:

Aier Eye Hospital (300015.CH) 22H1 – More Downside Ahead; The Long Logic Doesn’t Exist
Agilent Technologies: New Launches In Mass Spectrometry & Other Drivers
Pfizer Inc.: The Global Blood Therapeutics Acquisition & Other Drivers

Aier Eye Hospital (300015.CH) 22H1 – More Downside Ahead; The Long Logic Doesn’t Exist

The fundamental changes in the population structure will lead to a decline in the growth rate of the total retail sales of consumer goods. The long logic doesn’t exist.
Aier has hit a growth ceiling. As the endogenous demand will be stepped downward gradually, the performance of Aier will further decline. The downward elasticity of valuation is greater.
It is still difficult for healthcare sector to have its own independent growth logic. The bottom of healthcare sector would appear after the collapse of Aier’s valuation.

Agilent Technologies delivered an excellent quarterly result with earnings and revenue exceeding market expectations significantly.
The strong results were led by strength in its biggest markets i.e., chemical, energy, and pharma.
We provide the stock of Agilent Technologies with a ‘Hold’ rating with a revision in the target price.

While operating in a difficult foreign exchange environment, Pfizer maintained a good operational performance in the second quarter and delivered an all-around beat, exceeding Wall Street expectations on all counts.
The chance of a future variety that combines the severity of the original virus with the contagiousness of Omicron nevertheless persists.
Among major updates, Pfizer went on to acquire Global Blood Therapeutics to strengthen its commitment to sickle cell disease.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network